Application of powder X-ray diffraction in studying the compaction behavior of bulk pharmaceutical powders.
This study investigates the effects of crystal lattice deformation on the powder X-ray diffraction (PXRD) patterns of compressed polycrystalline specimen (compacts/tablets) made from molecular, crystalline powders. The displacement of molecules and the corresponding adjustment of interplanar distances (d-spacings) between diffracting planes of PNU-288034 and PNU-177553, which have crystal habits with a high aspect ratio favoring preferred orientation during tableting, are demonstrated by shifts in the diffracted peak positions. The direction of shift in diffracted peak positions suggests a reduction of interplanar d-spacing in the crystals of PNU-288034 and PNU-177553 following compaction. There is also a general reduction of peak intensities following compression at the different compressive loads. The lattice strain representing the reduction in d-spacing is proportional to the original d-spacing of the uncompressed sample suggesting that, as with systems that obey a simple Hooke's law relationship, the further apart the planes of atoms/molecules within the lattice are, the easier it is for them to approach each other under compressive stresses. For a third model compound comprising more equant-shaped crystals of PNU-141659, the shift in diffracted peak positions are consistent with an expansion of lattice spacing after compression. This apparent anomaly is supported by the PXRD studies of the bulk powder consisting of fractured crystals where also, the shift in peak position suggests expansion of the lattice planes. Thus the crystals of PNU-141659 may be fracturing under the compressive loads used to produce the compacts. Additional studies are underway to relate the PXRD observations with the bulk tableting properties of these model compounds.
Bandyopadhyay
Rebanta
R
Michigan Pharmaceutical Sciences, Pfizer Global Research and Development, Pfizer, Inc., Kalamazoo, Michigan 49001, USA. rebanta.bandyopadhyay@pfizer.com
Selbo
Jon
J
Amidon
Gregory E
GE
Hawley
Michael
M
D019245:Compressive Strength; D003460:Crystallization; D023303:Oxazolidinones / Q000737:chemistry*; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011208:Powders; D013607:Tablets; D014961:X-Ray Diffraction
D023303:Oxazolidinones; D004364:Pharmaceutical Preparations; D011208:Powders; D013607:Tablets